Summary
BeOne Medicines Ltd. reported a significant increase in cash and cash equivalents to $1.96 billion as of March 31, 2020, driven by substantial financing activities, including a major collaboration with Amgen that provided $2.78 billion in proceeds. Despite this strong liquidity, the company incurred a net loss of $364.9 million for the first quarter of 2020, a notable increase from the prior year's loss of $168.1 million. This widened loss is primarily attributed to a substantial rise in research and development (R&D) expenses, which increased by 70.6% to $304.3 million, and a significant increase in selling, general, and administrative (SG&A) expenses, up 85.8% to $107.1 million. The company's product revenue saw a decline of 9.3% to $52.1 million, impacted by decreased sales of in-licensed products like ABRAXANE and REVLIMID, as well as the suspension of ABRAXANE sales in China due to regulatory issues. However, the initial sales of its internally developed drugs, tislelizumab and BRUKINSA, provided some offset. Investors should note the significant increase in R&D spending, reflecting continued investment in pipeline development, and the ongoing impact of COVID-19 on commercial operations.
Financial Highlights
54 data points| Revenue | $52.06M |
| Cost of Revenue | $14.15M |
| Gross Profit | $37.91M |
| R&D Expenses | $304.30M |
| SG&A Expenses | $107.08M |
| Operating Expenses | $425.81M |
| Operating Income | -$373.76M |
| Interest Expense | $4.29M |
| Net Income | -$364.94M |
| EPS (Basic) | $-0.36 |
| EPS (Diluted) | $-0.36 |
| Shares Outstanding (Basic) | 1.01B |
| Shares Outstanding (Diluted) | 1.01B |
Key Highlights
- 1Total cash, cash equivalents, and short-term investments increased significantly to $3.4 billion as of March 31, 2020, primarily due to $2.78 billion in proceeds from the Amgen collaboration.
- 2Net loss widened to $364.9 million for Q1 2020, from $168.1 million in Q1 2019.
- 3Research and development (R&D) expenses increased by 70.6% to $304.3 million, driven by advancements in clinical drug candidates and collaboration expenses.
- 4Selling, general, and administrative (SG&A) expenses increased by 85.8% to $107.1 million, primarily due to increased headcount to support growing operations.
- 5Total revenues decreased by 33.1% to $52.1 million, mainly due to the absence of collaboration revenue from the terminated BMS agreement and a 9.3% decrease in product revenue.
- 6Product revenue declined 9.3% to $52.1 million, impacted by lower sales of in-licensed products and the suspension of ABRAXANE sales in China, partially offset by initial sales of tislelizumab and BRUKINSA.
- 7The company's net loss per ADS was $(4.70) for Q1 2020, compared to $(2.81) for Q1 2019.